Drug Profile
Research programme: placenta-derived stem cell therapies - Celgene
Alternative Names: Sickle cell anaemia cell therapy - CelgeneLatest Information Update: 04 Dec 2019
Price :
$50
*
At a glance
- Originator Celgene Corporation
- Class Stem cell therapies
- Mechanism of Action Cell replacements; Haematopoiesis modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Sickle cell anaemia
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 26 Jun 2013 No development reported - Preclinical for Sickle cell anaemia in USA (unspecified route)
- 24 May 2006 This programme is still in active development